期刊文献+

卡维地洛联合螺内酯治疗慢性心室重构性心力衰竭的研究 被引量:4

暂未订购
导出
摘要 目的研究卡维地洛联合螺内酯治疗慢性心室重构性心力衰竭疗效。方法将60例明确诊断心功能不全的患者随机分成治疗组和对照组各30例,对照组患者给予常规治疗(利尿剂、血管紧张素转化酶抑制剂,必要时给予洋地黄类药物)。观察组在常规治疗的基础上加用卡维地洛12.5~50.0mg/d和螺内酯20~40mg/d。疗程均为3个月。治疗3个月后按NYHA心功能分级标准评价心功能。治疗前、后分别测定心率、血压等,并行超声心动图检查,测定左室射血分数(LVEF)、每搏输出量(SV)、心脏指数(CI)。结果两组患者临床疗效间差异有非常显著性意义(P<0.01)。两组患者治疗前、后血压、心率、LVEF、SV、CI间差异均有非常显著性意义(P<0.01)。结论卡维地洛联合螺内酯治疗慢性心室重构性心力衰竭较常规治疗能更有效地改善患者的心功能,提高患者的治愈率。
出处 《实用心脑肺血管病杂志》 2007年第2期121-122,共2页 Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
  • 相关文献

参考文献7

  • 1李拥军,周秀娟,程蕴琳.卡维地洛与充血性心力衰竭[J].医学综述,2004,10(10):608-611. 被引量:12
  • 2Anonymous.Consensus recommendations for the management of chronic heart failure On behalf of the membership of the advisory council to im prove outcomes nationwide in heart failure[J].Am J Cardiol,1999,83:138.
  • 3Struthers AD.Aldostorone escape during ACE inihibitor therapy in chronic heart failure[J].Eur Heart J,1995,16:N103-106.
  • 4Bristow MR.Carvediol treatment of chronic heart failure:a newer[J].Heart,1998,79:8.
  • 5Stoschitz KY,Koshucharova,Zweiker R,et al.Differing beta-blocking effects of carvedilol and metoprolol[J].Heart Failure,2001,3:343-349.
  • 6Cargnoni A,Ceconic,Bemocchi P,et al.Reduction of oxidative stress by carvedilol:role in maintenance of ischaemic myocardium viability[J].Cardil-Vasc Res,2000,47:556-556.
  • 7Bristow MR.Mechanism of action of beta blocking agents in heart failure[J].Am J Cardiol,1997,80:26-40.

二级参考文献17

  • 1[1]Ruffolo RR, Feuerstein GZ. Carvedilol:preclinical profile and mechanisms of action in preventing the progression of congestive heart failure [J] .Eur Heart J, 1998,19[ Suppl B] :B19-B24.
  • 2[2]Esler M, Kaye D, Lambert G, et al. Adrenergic nervous system in Heart Failure[J] .Am J Cardiol, 1997,80(11A) :7L-14L.
  • 3[3]Bristow MR. Mechanism of action of beta-blocking agent in heart failure[J]. Am J Cardiol, 1997,80(llA) :26L-40L.
  • 4[4]Lohmeiar TE, Lohmeier JR, Warren S, et al. Sustained activation of the central baroreceptor pathway in angiotensin hypertension[J]. Hypertension,2002,39(2) :550-556.
  • 5[5]Lechat PP, Chalon S, Cucheat M, et al. Meta-analysis of randomized clinical trials on beta-blocker treatment in heart failure[J]. Circulation,1996,94[ Suppl I] :665.
  • 6[6]Packer M, Antonopoulos GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Result of a meta-analysis[ J] . Am Heart J, 2001,141 (6): 899-907.
  • 7[7]Azevedo ER, Kubo T, Mai S, et al. Nonselective versus selective betaedrenergic receptor blockade in congestive heart failure:differential effects on sympathetic activity [J]. Circulation, 2001,104 ( 18 ): 2194-2199.
  • 8[8]Vittorio TJ, Lang CC, Katz SD, et al. Vasopressor response to angiotensin Ⅱ infusion in patients with chronic heart failure receiving β-blockers[J]. Circulation, 2003,107(2): 290-293.
  • 9[9]Feuerstein GZ,Ruffolo RR.Carvedilol:a novel vasodilating beta-blocker with the potential for cardiovascular organ protection[J]. Eur Heart J, 1996,17[ Suppl B] :24-29.
  • 10[10]Ohlstein EH, Vickery L, Arleth A. Carvedilol prevents vascular and ventricular hypertrophy in spontaneously hypertensive rats[J]. Clin Exp Hypertension, 1994,16( 1 ): 163-167.

共引文献11

同被引文献36

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部